Biologics eat 51% of drug spending despite 5% of prescriptions, but FDA's new draft guidance hopes more competition can close that gap.
Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and ...
A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
CHMP backs a fifth teriparatide biosimilar as biosimilars in Europe grow, while US patent fights threaten new biologic competition.
Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.
A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results